| HOME >> BIOLOGY >> TECHNOLOGY |
--------- ---------- ---------- ----------
Net loss.................. $ (5,152) $ (27,113) $ (20,340) $ (36,394)
--------- ---------- ---------- ----------
--------- ---------- ---------- ----------
Basic and diluted loss
per share................ $ (0.26) $ (1.58) $ (1.04) $ (2.38)
--------- ---------- ---------- ----------
--------- ---------- ---------- ----------
Weighted average number of
common shares outstanding
(in thousands)........... 19,486 17,133 19,486 15,317
--------- ---------- ---------- ----------
--------- ---------- ---------- ----------
Oncothyreon Inc.(1)
Consolidated Balance Sheets Data
(in thousands of U.S. dollars, except share data)
(unaudited)
December 31, December 31,
2007 2006
Cash, cash equivalents and short term
investments.................................. $ 24,186 $ 28,395
Total assets.................................. $ 36,218 $ 33,456
Total long-term liabilities................... $ 12,526 $ 2,328
Shareholders' equity.......................... $ 12,019 $ 27,435
Common shares outstanding..................... 19,485,889 19,485,889
(1) On December 10, 2007, Oncothyreon became the successor corporation to
Biomira Inc. by way of a plan of arrangement effected pursuant to
Canadian law. These financial statements reflect the h
'/>"/>
| SOURCE Oncothyreon Inc. Copyright©2008 PR Newswire. All rights reserved |